The demonstration of PD-L1 expression in tumor-associated macrophages, the suggested activation/exhaustion profile of T cells in the MDA-MB-231 tumor, or the identification of different NK cell subsets in the A549 tumor provide key examples for the development of targeted therapies. This evidence concerns the gene CD274 and neoplasm.